Author

H. L. Chan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:cancer & tumor microenvironment· 4 Organism:human· 4 Research Focus:cell type annotation· 3 Research Focus:chromatin & epigenetic regulation· 2 Organism:mouse· 2 Assay:scRNA-seq· 2 Assay:bulk RNA-seq· 1

Frequent Co-Authors

F. Liu· 3 shared X. Hao· 3 shared C. H. Rivas· 2 shared D. G. Edwards· 2 shared D. Hoffman· 2 shared E. Chen· 2 shared H. Wang· 2 shared I. L. Bado· 2 shared

Activity by Year

2019-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

F. Liu

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Single cell profiling of bone metastasis ecosystems from multiple cancer types reveals convergent and divergent mechanisms of bone colonization.

F. Liu, Y. Ding, Z. Xu, X. Hao, T. Pan, G. Miles, C. H. Rivas, D. Hoffman, D. G. Edwards, E. Chen, H. Wang, H. L. Chan, J. Liu, L. Wu, L. Yu, , X. Zhang

The paper analyzes bone metastases from six cancer types using single-cell RNA-seq to identify three immune archetypes and their mechanisms of bone colonization.

bioRxiv · May 7, 2024Cancer Biology

Unbiased metastatic niche-labeling identifies estrogen receptor-positive macrophages as a barrier of T cell infiltration during bone colonization

Z. Xu, F. Liu, Y. Ding, T. Pan, Y.-H. Wu, J. Liu, I. L. Bado, W. Zhang, L. Wu, Y. Gao, X. Hao, L. Yu, D. G. Edwards, H. L. Chan, S. Aguirre, , X. H.- F. Zhang

bioRxiv · May 7, 2024 · PreprintCancer Biology

CBP/P300 BRD Inhibition Reduces Neutrophil Accumulation and Activates Antitumor Immunity in TNBC

X. Yuan, X. Hao, H. L. Chan, N. Zhao, D. A. Pedroza, F. Liu, K. Le, A. J. Smith, S. J. Calderon, N. Lieu, M. J. Soth, P. Jones, X. H.- F. Zhang, J. M. Rosen

CBP/P300 BRD inhibition reduces neutrophil accumulation and enhances antitumor immunity in neutrophil-enriched TNBC, improving responses to standard therapies.

bioRxiv · Apr 25, 2024 · PreprintCancer Biology

Methylation of histone H3 lysine 36 is a barrier for therapeutic interventions of head and neck squamous cell carcinoma.

L. Caeiro, Y. Nakata, R. L. Borges, L. Garcia-Martinez, C. Banuelos, S. Stransky, H. L. Chan, J. Brabson, D. Dominguez, Y. Zhang, P. W. Lewis, S. A. Benitah, L. Cimmino, D. Bilbao, S. Sidoli, , L. Morey

This study shows that H3K36M mutations in HNSCC create a therapeutic window by altering H3K27me3 levels, making tumors sensitive to PARP1/2 inhibitors or their combination with H3K27me3-upregulating agents.

bioRxiv · Nov 6, 2023Cancer Biology

PDGFRA Defines the Mesenchymal Stem Cell Kaposi’s Sarcoma Progenitors by Enabling KSHV Oncogenesis in an Angiogenic Environment

J. Naipauer, S. Rosario, S. Gupta, C. Premer, O. Mendez, M. Schlesinger, V. Ponzinibbio, V. Jain, L. Gay, R. Renne, H. L. Chan, L. Morey, D. Salyakina, M. Abba, S. Williams, , E. Mesri

The paper identifies PDGFRA+ bone marrow-derived mesenchymal stem cells as Kaposi’s sarcoma progenitors and shows pro-angiogenic conditions enable KSHV oncogenesis through epigenetic de-repression.

bioRxiv · Oct 2, 2019Cancer Biology